The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) has completed enrollment in a Phase 1 human trial in Tanzania to evaluate the safety and antiviral activity of a long-acting bispecific antibody, alone and in combination with another potent monoclonal antibody, to combat HIV.
Bispecific antibodies are lab-engineered antibodies designed to target two distinct binding sites on immune cells or virus envelopes. These molecules can neutralize HIV with improved breadth and potency, and they can be used as both preventive and therapeutic countermeasures.
Read more on DVIDS
here.